Allovate Therapeutics news

Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available without charge to allergy professionals facing difficulties bringing their patients into the office for injections. Allovate was founded in 2012 with the goal of improving and advancing the administration of allergy immunotherapy for patients of all ages. Allovate’s lead product, Allerdent®, is designed to deliver proteins, such as im

Allovate Therapeutics (“Allovate^®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce the appointment of Robert "Bob" Pomrenke to the position of Chief Executive Officer, effective April 1, 2019. Mr. Pomrenke brings over 25 years of sales, marketing and business development experience in the allergy immunotherapy market. He has held executive positions with Bayer Allergy Product/Hollister

Allovate, LLC, a specialty biopharmaceutical company, today announced that the company has signed an exclusive provider agreement with Restore Health to bring the new Allerdent OMIT System™, a personalized toothpaste system for the delivery of allergy immunotherapy, to patients nationwide.

Allerdent™ is the first oral mucosal immunotherapy (OMIT) toothpaste system designed to help moderate-to-severe allergy sufferers address the underlying cause of allergic response throug

Allovate, LLC, has signed an agreement with Restore Health, a company specializing in personalized medicine, for the exclusive rights to provide Allerdent™, a new personalized therapeutic toothpaste system for people suffering from allergic rhinitis.  Allerdent™ is designed for daily use as part of a normal tooth-brushing regimen and enables allergy sufferers to incorporate immunotherapeutic allergy t

Allovate Therapeutics, a biopharmaceutical company focused on improving treatment for allergies, announced today that the U.S Patent and Trademark Office (USPTO) has granted U.S. Patent No.  9,271,899 entitled, “Methods, Articles and Kits for Allergic Desensitization, via the Oral Mucosa.” The issuing patent including claims to the approach of combining allergenic proteins with toothpaste.

These claims provide patent protection for the oral mucosal immunotherapy (OMIT